newsfilter
← Latest News
GlobeNewswire·

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101

- Non-exclusive license for Solid's proprietary, next generation capsid, AAV-SLB101, to accelerate development of Kinea Bio's gene therapy for dysferlin-related limb-girdle muscular dystrophy - - Solid to receive an